The US FDA has approved Mitapivat (Aqvesme), the first oral treatment for anemia in adults with alpha or beta thalassemia. This breakthrough could reduce transfusion dependence, offering new hope for high-burden countries like India. Read more.
US FDA approves Mitapivat, the first oral therapy for thalassemia anemia. Indian hematologists welcome the breakthrough but highlight access and affordability challenges in India. Read more.
The US FDA has approved mitapivat (Aqvesme), the first oral drug treating anaemia in thalassaemia at a cellular level. Indian specialists explain its transformative potential for patients, especially in high-burden India.